Acute myeloid leukemia (AML) is a disease of the elderly. Poor outcomes with standard therapies necessitate novel approaches. Outpatient regimens sufficiently potent and well tolerated to induce remissions and enable continuation therapy may be beneficial. In this phase-1 study, we determined the maximum tolerated dose (MTD) and the efficacy for sequential azacitidine and lenalidomide as remission induction and continuation therapy in elderly, previously untreated patients. We investigated the impact on global DNA methylation and bone marrow cytokines, and sought biological predictors of response. Eighteen patients were enrolled. The MTD was not reached. Median follow-up was 8.2 months (10.3 months for survivors). Common adverse events included fatigue, injection site reactions, constipation, nausea, pruritus and febrile neutropenia. Ten patients responded (56%), and the rate of complete remissions (CRs) or CRs with incomplete recovery of blood counts for evaluable patients was 44% (7/16). The median response duration was 6.2 months. DNA demethylation and changes in bone marrow cytokines were observed; responders had a unique cytokine profile and a trend towards lower methylation levels. Sequential azacitidine and lenalidomide was well tolerated with encouraging clinical and biological activity in previously untreated elderly AML patients. This trial is registered at ClinicalTrials.gov (NCT00890929).
INTRODUCTION
With a median age at diagnosis of 72, 1 acute myeloid leukemia (AML) represents a major therapeutic challenge when diagnosed in elderly patients. Whereas advances in supportive care and regimen intensification have benefited younger patients, outcomes for the elderly have not substantially improved. 2 Older age is an adverse prognostic factor associated with increased comorbidities 3 as well as high-risk biological features. 3 --5 As a result, long-term overall survival occurs in only about 5% of elderly patients treated with conventional regimens. 6 Furthermore, a significant number are not candidates for stem cell transplantation, 7 precluding a curative option. Therefore, it is rational to consider tolerable regimens that can induce and maintain responses in elderly AML patients.
DNA methyltransferase enzymes add methyl groups to genomic CpG sites. CpG dinucleotides are enriched at certain gene promoter regions and methylation of these sites may contribute to leukemogenesis through silencing of tumor suppressor genes. 8, 9 Aberrant methylation is more common in older cancer patients 10 and is pharmacologically reversible. Azacitidine, an azanucleoside DNA methyltransferase inhibitor that is approved by the US Food and Drug Administration in the related myeloid malignancy myelodysplastic syndrome (MDS), 11 is associated with a low response rate (B20%) in elderly AML patients. 12 Lenalidomide is an immunomodulatory agent, Food and Drug Administration approved for use in MDS with del(5q) and in multiple myeloma. 13 In various diseases it regulates immune responses, gene expression, phosphatase activity, angiogenesis and cytokines, 13 --16 and has demonstrated single-agent activity when used as primary and salvage therapy in AML. 17, 18 Lenalidomide may upregulate tumor suppressor genes activated by azacitidine; 15 in addition, lenalidomide has epigenetic modifying properties in multiple myeloma cell lines, 19 which may be additive or synergistic in combination with azacitidine. 16 The CR rate for single-agent high-dose lenalidomide in elderly patients with AML was 30%; 18 high-risk MDS patients who received both azacitidine and lenalidomide had a CR rate of 44%. 20 This combination has never been tested in AML. We administered sequential azacitidine and lenalidomide to elderly, previously untreated AML patients to induce remission, and then continued therapy at the same dose and schedule in a phase-1, open-label dose escalation trial.
Our primary objective was to determine the maximum tolerated dose (MTD) and adverse event (AE) profile of lenalidomide when used sequentially with azacitidine. Secondary objectives were to determine the clinical efficacy (response rate, response duration and early mortality), changes in genome-wide DNA methylation and cytokine profiles, and whether pre-treatment DNA methylation or cytokine profiles could predict responders.
PATIENTS AND METHODS

Patient population
From April 2009 to May 2010, 20 patients were considered for this study; 18 met inclusion criteria and were enrolled. All had World Health Organizationconfirmed diagnoses of AML other than acute promyelocytic leukemia, were X60 years, not eligible for or not interested in conventional therapies, and had not received lenalidomide or prior AML treatment. Patients had an Eastern Cooperative Oncology Group performance status of p2, creatinine o1.5 mg/dl, total bilirubin p1.5 times the upper limit of normal and transaminase levels p2.5 times the upper limit of normal. White blood cell count was required to be p10 000 K/ml at the initiation of treatment, but use of hydroxyurea to attain this was permitted; no patients were ultimately excluded because of refractory elevated white blood cell count. Patients were excluded for advanced hepatic tumors, active opportunistic infections or concomitant chemotherapy.
Study design
The first cohort received 7 days of azacitidine 75 mg/m 2 /day intravenously or subcutaneously, followed by observation for 21 days (cycle 0). If tolerated, these patients then received azacitidine 75 mg/m 2 /day followed by 5 mg of lenalidomide orally for 21 days. This was followed by 14 days of observation, for a total 42-day cycle. The three subsequent cohorts omitted cycle 0; these patients received the same dose and schedule of azacitidine with a dose escalation of lenalidomide (Figures 1a --c) . Dose-limiting toxicities (DLTs) were defined as toxicity-related dose delays 28 days or grade 4 (or select grade 2 or 3) non-hematologic toxicity. Hematologic toxicity was not evaluable in patients with baseline neutropenia or thrombocytopenia; these patients were administered 42-day treatment cycles with supportive care measures as needed. For patients with an absolute neutrophil count '500/mm 3 or a non-transfused platelet count of 420 000/mm 3 at baseline, hematologic toxicity was defined, in the absence of disease progression, as an absolute neutrophil count o500/mm 3 or a platelet count o20 000/mm 3 on day 28 of cycle 0 or day 42 of cycle 1. Evaluable patients who did not recover their counts because of regimen-related toxicity (defined by no evidence of disease in the bone marrow) waited for their counts to recover before initiating the next cycle. A typical '3 þ 3' dose escalation schema was followed. 21 Decisions to dose escalate were made based on dose-limiting toxicity that occurred during the first cycle or for patients in the first cohort, during the zero or first cycle.
A bone marrow biopsy and aspirate was performed within 28 days of enrollment and was repeated to assess responses after cycles 0, 1, 3, 6 and 12. Patients could receive 12 cycles; those with a complete remission (CR) or CR with incomplete recovery of blood counts (CRi), partial remission (PR) or stable disease continued, provided they did not experience toxicity.
Study assessments and statistical analysis
Toxicities were scored using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.
22 A serious AE was an AE that resulted in death or immediate risk of death, prolonged hospitalization or substantial disability. Responses were assessed according to the LeukemiaNet guidelines. 23 Patients who completed one full cycle of treatment were considered evaluable. Cytogenetic risk was assessed by Southwest Oncology Group criteria. 24 Kaplan --Meier analysis was used to estimate response duration and overall survival. Impact of clinical characteristics on outcomes was assessed by unpaired Student's t-tests.
Processing of biological samples
Bone marrow aspirate was collected in heparin or ethylenediaminetetraacetic acid tubes. The samples were diluted 4x with PBS before the addition of Ficoll --Hypaque (Sigma-Aldrich, St Louis, MO, USA) density gradient. After centrifugation, the plasma and mononuclear layers were collected and stored at À80 1C.
Molecular mutations
Screening for mutations in FMS-like tyrosine kinase 3 internal tandem duplication (FLT-3-ITD) and D835 tyrosine kinase domain (FLT-3-TKD), nucleophosmin (NPM1c), CCAAT enhancer binding protein alpha (CEBPA), isocitrate dehydrogenase 1(IDH1; R132, R100 and IDH2; R172, R140) and 10 --11 translocation 2 was performed as previously described. 25 --28 DNA methylation microarrays and data analysis
The HpaII tiny fragment enrichment by ligation-mediated PCR (HELP) assay was performed as previously described, 29 design name: 100128_HG19_MKF_HELP_ChIP_HX3, design ID: 11291), based on the GRCh37/HG19 assembly of the human genome. Data preprocessing and normalization were performed as previously described. 30 Statistically significant differentially methylated regions between pretreatment and post-treatment samples were identified using a moderated paired t-test. Differences between responders and non-responders were assessed using a t-test for unequal variances. All P-values were adjusted using Benjamini --Hochberg's correction for multiple testing. A further significance cutoff requiring a log 2 mean sample difference of 41.5 was included to ensure the capture of biologically significant differences. Some patients from the phase-2 portion of the study were included in this analysis.
Cytokine profiling and data analysis 51-Plex kits from Affymetrix (Santa Clara, CA, USA) were used according to manufacturer's recommendation. Each sample was measured in duplicate.
Plates were read using a Luminex LabMap200 (Luminex, Austin, TX, USA) instrument with a lower bound of 100 beads per sample per cytokine. Oneway ANOVA compared the mean differences in log-transformed average mean fluorescence intensity (MFI) values of each cytokine in a group of pre-and post-treatment patients. The P-values were adjusted for multiple hypotheses testing using a q-value (q), an estimate of the false discovery rate, using the q value package in R (version 2.12.1). The cytokines with false discovery rate (q) o10% were considered significant. The absolutefold change was the ratio of the average mean --fluorescence intensity value of post-to pre-treatment samples. We repeated the same procedure to identify the cytokines with significant differences in the expression between responders (CR/CRi) and non-responders. Some patients from the phase-2 portion of the study were included in this analysis.
Study oversight
The study was approved by Stanford University's institutional review board and performed in accordance with the principles of the Declaration of Helsinki. All patients provided written informed consent. The trial was registered at ClinicalTrials.gov (NCT00890929).
RESULTS
Patients
Of 20 patients screened, 18 were enrolled. One was excluded for elevated creatinine and one did not have AML. The majority (56%) had myelodysplasia-related changes. The median age was 72 (range 62 --86). Twelve of eighteen (67%) patients had intermediate cytogenetics. See Table 1 MTD and safety profile There were no dose-limiting toxicities in the first three cohorts. Dose-limiting toxicity (grade 4 neutropenic fever) occurred in one of the six patients in cohort 4; therefore, the MTD was not reached. A total of 17 serious AEs occurred in 11 patients (Table 2) . Of the 13 patients evaluable for thrombocytopenia at baseline, 2 experienced grade 3 thrombocytopenia; of the 6 patients evaluable for neutropenia at baseline, 3 experienced grade 3 neutropenia. One patient required a 14-day dose delay for myelosuppression between the third and fourth cycles, and one patient prematurely discontinued the second cycle due to rash. Ten patients (56%) had neutropenic fevers. See Supplementary Table 1 for the most common grade 1 and 2 AEs.
Efficacy
Eight patients (44%) are alive with at least 8 months of follow-up (Table 3 ). In the first cohort, two patients were replaced because of disease progression before completion of cycle 0, and considered un-evaluable. Ten patients responded, for an overall response rate (ORR ¼ CR þ CRi þ PR) of 56% (10/18). The overall response rate for evaluable patients was 63% (10/16). Seven had a CR/CRi, with four CRs and three CRis (39% of total patients and 44% of evaluable patients). Three had a partial remission (17% of total patients and 19% of evaluable patients). The overall response rate for post-cohort 1 patient was 10/13 (77%), with a CR/CRi rate of 7/13 (54%). Ten patients died. Two died in the first 60 days (11%) of disease progression. Four others died of disease progression (total 38%) after 60 days. One died of sepsis and three from bleeding complications. One-third of the patients did not require hospitalization. The median number of cycles to achieve best response was 2.5 (range 1 --6). Median response duration was 6.2 months (range 1.4 --13.4); the median overall survival was 8.2 months (range 0.7 --16.0) (Figure 3) . No patients who achieved a CR/CRi experienced bone marrow aplasia (cellularity o10%). One patient achieved a cytogenetic CR and one retained a chromosomal abnormality after achieving a morphological remission. Three of ten patients with AML myelodysplasia-related changes had a CR/ CRi; two of these patients also had morphological resolution of dysplasia. Lower bone marrow blasts at diagnosis was associated with CR/CRi (5/6 with blasts o50% had CR/CRi vs 2/9 with blasts 450% had CR/CRi, P ¼ 0.02).
To compare outcomes from this regimen with the use of standard induction, we used a web-based application, 31 based on a large dataset of elderly AML patients given standard induction, 32 to predict the CR and early death rate of our patients had they been induced (Supplementary Table 2 ). The predicted median CR rate of 49% was similar to our 44% CR/CRi rate for evaluable patients (95% exact confidence interval 22--69%). However, the 60-day mortality rate of 11% (95% exact confidence interval 1.4--35%) noted in our study compared favorably with the predicted 25% early death rate had our patients received standard induction.
HpaII tiny fragment enrichment by ligation-mediated PCR assay for DNA methylation profiling of primary samples We compared pre-and post-treatment DNA methylation profiles for 11 patients. The supervised analysis showed treatment resulted in marked genome-wide DNA demethylation, as evidenced by the asymmetry of the dot blot branches shown in Figure 4a . Using a false discovery rate of 5% and an absolute log 2 methylation change of 1.5, which corresponds to a X20% change in methylation, treatment resulted in 250 differentially methylated regions, corresponding to 350 unique genes (Supplementary Figure 1 and Supplementary Table 3) . Next, we compared the baseline methylation profiles of seven patients who achieved a CR/CRi with those of seven non-responders. Whereas the asymmetric branches of the dot plot in Figure 4b indicate a trend towards differential methylation, this was not statistically significant. However, a log 2 methylation difference 41.5 between the groups was observed for 92 genes, with non-responders having greater relative methylation (Figure 4b ).
Bone marrow cytokine expression profiling Using a flow-cytometry based Luminex 200 IS platform (Luminex) we measured levels of 51 human cytokines in patient samples (Supplementary Table 4 ). We found significant increases in the levels of nine cytokines when comparing baseline and posttreatment samples from 18 patients. (Table 4 ) Decreased levels of five cytokines at baseline were significantly associated with responses. (Table 5 ) Two cytokines, IL-17 and macrophage colony-stimulating factor, were significantly decreased in responders and significantly increased after treatment (q ¼ 0.075 and 0.04, respectively). 
DISCUSSION
We report in this small cohort of elderly, previously untreated AML patients that the sequential combination of azacitidine and lenalidomide is well tolerated with low early-death rates, has encouraging clinical activity and allows for continued therapy in the outpatient setting. For patients who completed at least one cycle of therapy, the overall response rate was 63% with a CR/CRi rate of 44% and the median overall survival was roughly 8 months. AEs were fairly evenly distributed across cohorts. Fatigue and infectious complications were common. Neutropenia did not increase with dosage and was mostly indistinguishable from disease-related cytopenias. Pruritus and rash nearly completely resolved after several days and typically did not recur, or were significantly diminished, after the first cycle. Although the majority of patients (67%) required hospitalization, these events occurred predominately during the first cycle of therapy, before responses were noted. Once patients responded, hospitalizations were less frequent. The MTD was not reached; as a single agent in a similar population, 50 mg of lenalidomide was found to be the MTD 17 and therefore further dose escalation was not attempted. The recommended phase-2 dose and schedule is azacitidine 75 mg/m 2 /day on days 1 --7, lenalidomide 50 mg on days 8 --28 and observation on days 29 --42.
Since epigenetically directed therapies given beyond achievement of clinical responses may be beneficial, 33 we aimed to adapt this strategy to elderly AML patients by devising an effective outpatient remission induction regimen that was sufficiently well tolerated so as to also be used as continuation therapy at the same intensity as administered for induction. A randomized discontinuation protocol planned for the phase-2 portion of this study may help to determine if continuation therapy is beneficial in this population.
It is unclear, from our study and another using this combination in MDS, whether the therapeutic benefit is due to azacitidine, lenalidomide, or an additive or even synergistic interaction between the two agents. 34 However, the CR/CRi rate in evaluable patients of 44% in this study (39% for total patients) exceeds the reported CR rate for azacitidine alone (20%), 12 and the CR/CRi rate for lenalidomide alone (30%). 18 Results from the phase-2 portion of this study will more accurately determine the response rate associated with the sequential combination of azacitidine and lenalidomide, allowing a more direct comparison. Finally, a comparison of genome-wide DNA methylation and circulating cytokines after azacitidine alone and after azacitidine plus lenalidomide in the same patients is underway, and may help to further clarify the mechanism of each agent.
Because this combination has been successfully utilized, at a different dose and schedule, for high-risk MDS, we noted its impact on underlying dysplasia in our patients. Three of ten patients with AML myelodysplasia-related changes responded; two also had resolution of dysplasia and transfusion dependence, suggesting that for some patients, this regimen may be effective for both the underlying MDS and the leukemic clone.
Recent results of a single-agent lenalidomide clinical trial 18 prompted us to perform several post-hoc analyses. Using our schedule of sequential azacitidine and lenalidomide, we also observed that a lower baseline bone marrow blast count predicted CR/CRi (83% vs 22% CR/CRi rate for bone marrow blast count o50% and 50%, respectively; P ¼ 0.02). These data suggest that patients with a smaller 'disease burden' may be the best candidates for this and related therapies. The patients in this study were unfit or unwilling to undergo induction chemotherapy. We observed a similar CR/CRi rate as would be expected from conventional induction therapy, with a lower early-death rate. 32 One possible explanation for the low early mortality associated with this regimen is the absence of bone marrow aplasia in patients who achieved a CR/CRI, an observation also made in the setting of single-agent lenalidomide. 18 The ability to provide a regimen with equivalent efficacy and less toxicity than standard induction should be explored further in elderly patients with AML.
This HpaII tiny fragment enrichment by ligation-mediated PCR assay represents the largest number of HpaII amplifiable fragments studied in a clinical dataset to date. We hypothesized that patients with increased methylation at baseline would be more likely to respond. However, in this small series, there was a trend towards relative hypermethylation in non-responders. Perhaps a larger sample size will help to further elucidate this observation; alternative mechanisms for the activity of this combination are being studied.
Lenalidomide modulates cytokines, 35 and cytokine signatures can predict outcomes in patients with AML. 36 Although we are unable to draw mechanistic conclusions, we observed that patients exposed to this regimen experienced significant increas in specific bone marrow cytokines, including those involved in differentiation (macrophage colony-stimulating factor and granulocyte colony-stimulating factor) and hematopoiesis stem cell factor. In patients who received induction chemotherapy, high expression of macrophage colony-stimulating factor-receptor and granulocyte colony-stimulating factor-receptor and low expression of stem cell factor-receptor have been shown to correlate with a better prognosis. 37 In our sample set, a subset of cytokines was associated with response when decreased at baseline (Table 5) ; two of these (macrophage colony-stimulating factor and IL-17) were also significantly increased after treatment, suggesting that for certain patients increase in specific cytokines may be a marker of response.
Therefore, it may be feasible to prospectively identify those patients who are most likely to respond to this or similar regimens based on methylation and cytokine profiles. However, because of shows the regimen's demethylating effects, as illustrated by the asymmetric branches. 'Stringent' differentially methylated probe sets, defined by both a false discovery rate o0.05 and absolute log 2 methylation difference 41.5, are highlighted in red, whereas blue dots represent probe sets that reached statistical significance but not an absolute log 2 methylation difference 41.5.
(b) Dot-plot representation of methylation differences between nonresponders and those who achieved a CR or CRi of peripheral blood counts (x axis) vs statistical significance (y axis).
limitations in sample size, hypotheses regarding the biological relevance of these findings remain speculative.
In conclusion, the sequential combination of azacitidine and lenalidomide in elderly, previously untreated AML patients was well tolerated and effective, particularly for those with a smaller disease burden. Although the mechanisms remain unknown, we observed DNA demethylation and alterations in bone marrow cytokines. Finally, biological signatures and percentage of bone marrow involvement may predict responders to this regimen. The high overall and CR rate are promising and a phase-2 study is ongoing. 
